High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C

Haematologica

Volumn 91, Issue 10, 2006, Pages 1367-1371

  Mancuso, Maria Elisa ^a   Rumi, Maria Grazia ^b,c   Santagostino, Elena ^a   Linari, Silvia ^d   Coppola, Antonio ^e   Mannucci, Pier Mannuccio ^a,f   Colombo, Massimo ^b,c  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Regina Elena Hospital   (Italy)

^d CAREGGI UNIVERSITY HOSPITAL   (Italy)

^e FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^f NONE   (Italy)

Author keywords

Clinical observations; Interventions; Therapeutic trials

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GENOTYPE; HEADACHE; HEMOPHILIA; HEPATITIS C; HUMAN; INJECTION SITE REACTION; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; SIDE EFFECT; THYROID DISEASE; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION;

ADULT; DRUG THERAPY, COMBINATION; FEMALE; HEMOPHILIA A; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RIBAVIRIN;

EID: 33750015977     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006;130:231-64.
2. Rumi MG, Colombo M, Gringeri A, Mannucci PM. High prevalence of antibody to hepatitis C virus in multitransfused hemophiliacs with normal transaminase levels. Ann Intern Med 1990;112:379-80.
3. Darby SC, Ewart DW, Giangrande PLF, Spooner RJ, Rizza CR, Dusheiko GM, et al. Mortality form liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997;350:1425-31.
4. Goedert JJ, Eyster ME, Lederman MM, Mandalaki T, De Moerloose P, White GC 2nd, et al. End-stage liver disease in persons with hemophilia and trasfusion-associated infections. Blood 2002; 100:1584-9.
5. Lindsay KL. Introduction to therapy of hepatitis C. Hepatology 2002;36:S114-S20.
6. Meijer K, Smid WM, van der Meer J. Treatment of chronic hepatitis C in haemophilia patients. Haemophilia 2000;6:605-13.
7. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, ShifFman M, Reindollar R, et al. Peginterferon a-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
8. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon a-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
9. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-a2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-55.
10. Rumi MG, Santagostino E, Morfini M, Gringeri A, Tagariello G, Chistolini A, et al. A multicenter controlled, randomized, open trial of Interferon a2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C. Blood 1997; 89:3529-33
11. Fried MW, Peter J, Hoots K, Gaglio PJ, Talbut D, Davis PC, et al. Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon a-2b and ribavirin. Hepatology 2002;36:967-72.
12. Santagostino E, De Filippi F, Rumi MG, Colombo M, Mannucci PM. Sustained suppression of hepatitis C virus by high doses of interferon and ribavirin in adult hemophilic patients. Transfusion 2004;44:790-4.
13. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, et al. Pegylated interferon-a2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000;68:556-67.
14. Kozlowski A, Charles SA, Harris JM. Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs 2001;15:419-29.
15. Soffredini R, Rumi MG, Parravicini ML, Ronchi G, Del Ninno E, Russo A, et al. Serum levels of hepatitis C virus core antigen as a marker of infection and response to therapy. Am J Gastroenterol 2004;99:1738-43.
16. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with Peginterferon a-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-52.
17. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. Hepatology 2002;36 Suppl 1:S121-S7.
18. Davis GL, Lau JYN. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997; 26 Suppl 1: S122-S7.
19. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of IFN-a therapy. Science 1998;282:103-7.
20. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon a-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006;44:97-103.
21. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon a2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352:1426-32.
22. Dalgard O, Bjoro K, Helium KB, Myrvang B, Ritland S, Skaug K, et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004;40:1260-5.
23. Sherman IA, Pappas SC, Fisher MM. Hepatic microvascular changes associated with development of liver fibrosis and cirrhosis. Am J Physiol 1990;258:H460-H5.
24. Zeuzem S, Feinman SV, Rasenack J. Peginterferon a-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-72.
25. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061-9.